The Oxford Study for Biomarkers in MND (‘BioMOx’) is pleased to announce Phase 2. This is focused on the clinical translation of candidate biomarkers (MRI and neurochemical), and the exploration of pre-symptomatic events through the study of individuals carrying genetic mutations linked to ALS.
This has been funded through the Medical Research Council & MND Association Lady Edith Wolfson Senior Clinical Fellowship awarded to Dr Martin Turner. As well as access to state-of-the-art 7-Tesla MRI at FMRIB, the Oxford MND Centre has a new collaboration with the Oxford Centre for Human Brain Activity (OHBA) to incorporate magnetoencephalography (MEG). This will be a valuable addition in our desire to begin to define pathology in ALS at the systems-level. Oxford is also contributing to the JPND-funded ‘SOPHIA’ EU consortium, advancing the goal of standardization and harmonization of clinical, imaging and neurochemical data.
MEG is capable of over 300 simultaneous recordings of brain activity and adds unique temporal resolution to the anatomical detail that MRI provides.